Aclaris Therapeutics (ACRS) Retained Earnings: 2017-2025
Historic Retained Earnings for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$948.0 million.
- Aclaris Therapeutics' Retained Earnings fell 17.57% to -$948.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$948.0 million, marking a year-over-year decrease of 17.57%. This contributed to the annual value of -$902.9 million for FY2024, which is 17.13% down from last year.
- Aclaris Therapeutics' Retained Earnings amounted to -$948.0 million in Q3 2025, which was down 1.56% from -$933.4 million recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Retained Earnings peaked at -$533.3 million during Q1 2021, and registered a low of -$948.0 million during Q3 2025.
- Moreover, its 3-year median value for Retained Earnings was -$798.7 million (2024), whereas its average is -$826.0 million.
- Data for Aclaris Therapeutics' Retained Earnings shows a maximum YoY declined of 18.01% (in 2021) over the last 5 years.
- Aclaris Therapeutics' Retained Earnings (Quarterly) stood at -$595.4 million in 2021, then declined by 14.60% to -$682.3 million in 2022, then declined by 12.97% to -$770.8 million in 2023, then dropped by 17.13% to -$902.9 million in 2024, then decreased by 17.57% to -$948.0 million in 2025.
- Its Retained Earnings was -$948.0 million in Q3 2025, compared to -$933.4 million in Q2 2025 and -$917.9 million in Q1 2025.